BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27225749)

  • 1. Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer.
    Shinohara S; Hanagiri T; Taira A; Takenaka M; Oka S; Chikaishi Y; Uramoto H; So T; Yamada S; Tanaka F
    Oncology; 2016; 90(6):327-38. PubMed ID: 27225749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
    Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
    Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
    Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer.
    Miyoshi T; Kondo K; Hino N; Uyama T; Monden Y
    Clin Cancer Res; 1997 Aug; 3(8):1289-97. PubMed ID: 9815811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44 splicing pattern is associated with disease progression in pulmonary adenocarcinoma.
    Lee LN; Kuo SH; Lee YC; Chang YL; Chang HC; Jan IS; Yang PC
    J Formos Med Assoc; 2005 Aug; 104(8):541-8. PubMed ID: 16193174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and significance of E-cadherin, CD44v6, and proliferating cell nuclear antigen in non-small cell lung cancer].
    Weng MX; Wu CH; Yang XP
    Ai Zheng; 2008 Feb; 27(2):191-5. PubMed ID: 18279620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.
    Sun BS; Li Y; Zhang ZF; You J; Wang CL
    Ann Thorac Surg; 2013 Dec; 96(6):1943-51. PubMed ID: 24094519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of ezrin in human non-small cell lung cancer and its relationship with metastasis and prognosis].
    Chen QY; Yan J; Hu HZ; Chen FY; Song J; Jiang ZY; Jiao DM; Wu YQ
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):436-40. PubMed ID: 22967445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.
    Le QT; Chen E; Salim A; Cao H; Kong CS; Whyte R; Donington J; Cannon W; Wakelee H; Tibshirani R; Mitchell JD; Richardson D; O'Byrne KJ; Koong AC; Giaccia AJ
    Clin Cancer Res; 2006 Mar; 12(5):1507-14. PubMed ID: 16533775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
    D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
    Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
    Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
    J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy.
    Tei H; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jul; 32(5):694-700. PubMed ID: 24468288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
    Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
    Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of CD44 variant exon 6 in lung cancers].
    Wang FL; Wei LX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):401-2. PubMed ID: 12940087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
    Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
    Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The expression of vascular endothelial growth factor, CD44v6 in non-small cell lung carcinoma].
    Mei TH; Zhang GR; Ma Y
    Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):647-50. PubMed ID: 15329250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.